Taking its turn before a joint meeting of the Anesthetic and Analgesic Drug Products and the Drug Safety and Risk Management advisory committees (adcom), Collegium Pharmaceutical Inc. faced many of the same questions about its tamper-resistant, extended-release (ER) oxycodone candidate, Xtampza (formerly COL-003), that Purdue Pharma LP incurred the previous day about Avridi, its immediate-release oxycodone tablet.